新药研发中的结核病化学生物学。
The chemical biology of new drugs in the development for tuberculosis.
机构信息
Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, United States.
出版信息
Curr Opin Chem Biol. 2010 Aug;14(4):456-66. doi: 10.1016/j.cbpa.2010.04.008. Epub 2010 May 7.
Abstract
With the worldwide emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (Mtb), there are serious concerns about the continued ability to contain this disease. We discuss the most promising new drugs in late-stage development that might be useful in treating MDR and XDR forms of the disease. These agents have novel mechanisms of action that are not targeted by the standard drugs used presently to treat susceptible strains.
摘要
随着全球耐多药（MDR）和广泛耐药（XDR）结核分枝杆菌（Mtb）菌株的出现，人们严重担心能否继续控制这种疾病。我们讨论了处于后期开发阶段的最有前途的新药，这些药物可能对治疗 MDR 和 XDR 形式的疾病有用。这些药物具有新颖的作用机制，目前用于治疗敏感菌株的标准药物并未针对这些机制。
相似文献
1
The chemical biology of new drugs in the development for tuberculosis.新药研发中的结核病化学生物学。
Curr Opin Chem Biol. 2010 Aug;14(4):456-66. doi: 10.1016/j.cbpa.2010.04.008. Epub 2010 May 7.
2
Extensively drug-resistant tuberculosis: new strains, new challenges.广泛耐药结核病：新菌株，新挑战。
Expert Rev Anti Infect Ther. 2008 Oct;6(5):713-24. doi: 10.1586/14787210.6.5.713.
3
Classical against molecular-genetic methods for susceptibility testing of antituberculotics.经典方法与分子遗传学方法在抗结核药物药敏试验中的比较。
Adv Exp Med Biol. 2015;835:15-22. doi: 10.1007/5584_2014_28.
4
Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.2015 年，乌克兰出现了耐多种药物和广泛耐药结核分枝杆菌北京家族。
Emerg Infect Dis. 2020 Mar;26(3):481-490. doi: 10.3201/eid2603.190525.
5
Genotypes and drug susceptibility of Mycobacterium tuberculosis Isolates in Shihezi, Xinjiang Province, China.中国新疆石河子结核分枝杆菌分离株的基因型及药物敏感性
BMC Res Notes. 2012 Jun 19;5:309. doi: 10.1186/1756-0500-5-309.
6
First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant in Saudi Arabia.沙特阿拉伯对耐多药菌氟喹诺酮和氨基糖苷类耐药性的首次洞察。
Am J Trop Med Hyg. 2017 May;96(5):1066-1070. doi: 10.4269/ajtmh.16-0579.
7
Differential DNA methylomes of clinical MDR, XDR and XXDR isolates revealed by using single-molecule real-time sequencing.采用单分子实时测序技术揭示临床耐多药、广泛耐药和超级耐药分离株的差异 DNA 甲基组。
J Drug Target. 2021 Jan;29(1):69-77. doi: 10.1080/1061186X.2020.1797049. Epub 2020 Jul 29.
8
4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.4H-1,3-苯并噻嗪-4-酮：一种有前途的耐多药/广泛耐药结核病治疗药物。
Curr Top Med Chem. 2019;19(8):567-578. doi: 10.2174/1568026619666190305130809.
9
Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan.巴基斯坦广泛耐药结核分枝杆菌分离株耐药突变特征。
Antimicrob Agents Chemother. 2011 Dec;55(12):5654-9. doi: 10.1128/AAC.05101-11. Epub 2011 Sep 12.
10
Correlations between drug resistance of Beijing/W lineage clinical isolates of Mycobacterium tuberculosis and sublineages: a 2009-2013 prospective study in Xinjiang province, China.结核分枝杆菌北京/W 家族临床分离株耐药性与亚家族之间的相关性：2009 - 2013年中国新疆前瞻性研究
Med Sci Monit. 2015 May 7;21:1313-8. doi: 10.12659/MSM.892951.
引用本文的文献
1
Indole-fused spirochromenes as potential anti-tubercular agents: design, synthesis and in vitro evaluation.吲哚稠合螺色烯作为潜在的抗结核药物：设计、合成和体外评价。
Mol Divers. 2021 Nov;25(4):2137-2148. doi: 10.1007/s11030-020-10108-z. Epub 2020 May 30.
2
Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.联合化学遗传学和数据驱动的生物信息学方法鉴定受体酪氨酸激酶抑制剂作为宿主导向的抗菌药物。
Nat Commun. 2018 Jan 24;9(1):358. doi: 10.1038/s41467-017-02777-6.
3
Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.双螺环色满酮类化合物作为结核分枝杆菌有效的抑制剂：合成与生物评价。
Mol Divers. 2017 Nov;21(4):999-1010. doi: 10.1007/s11030-017-9779-y. Epub 2017 Aug 24.
4
Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.一种可杀死非复制型结核分枝杆菌的卡普霉素类似物的发现及其与转位酶I抑制剂的协同作用。
J Antibiot (Tokyo). 2015 Apr;68(4):271-8. doi: 10.1038/ja.2014.133. Epub 2014 Oct 1.
5
Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.一种水溶性脂质I类似物的生物合成及转位酶I的简便测定法。
Anal Biochem. 2014 Sep 15;461:36-45. doi: 10.1016/j.ab.2014.05.018. Epub 2014 Jun 2.
6
Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis.替比培南，一种新型碳青霉烯类抗生素，是一种缓慢的底物，可抑制结核分枝杆菌的β-内酰胺酶。
Biochemistry. 2014 Jun 10;53(22):3671-8. doi: 10.1021/bi500339j. Epub 2014 May 29.
7
Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds.探索药用植物内生菌作为抗分枝杆菌化合物来源的潜力。
Microbiol Res. 2014 Jul-Aug;169(7-8):483-95. doi: 10.1016/j.micres.2013.12.009. Epub 2014 Jan 15.
8
Bisubstrate Inhibitors of Biotin Protein Ligase in Resistant to Cyclonucleoside Formation.抗环核苷形成的生物素蛋白连接酶双底物抑制剂
ACS Med Chem Lett. 2013 Dec 12;4(12):1213-7. doi: 10.1021/ml400328a.
9
Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.结核分枝杆菌细胞包膜生物发生靶向治疗的研究进展。
Future Microbiol. 2013 Jul;8(7):855-75. doi: 10.2217/fmb.13.52.
10
Kinetics of IFN-gamma and TNF-alpha gene expression and their relationship with disease progression after infection with Mycobacterium tuberculosis in guinea pigs.豚鼠感染结核分枝杆菌后 IFN-γ 和 TNF-α 基因表达的动力学及其与疾病进展的关系。
Yonsei Med J. 2013 May 1;54(3):707-14. doi: 10.3349/ymj.2013.54.3.707.
本文引用的文献
1
Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.合成和评价 SQ109 类似物作为潜在的抗结核候选药物。
Eur J Med Chem. 2010 May;45(5):2075-9. doi: 10.1016/j.ejmech.2010.01.046. Epub 2010 Jan 28.
2
Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.结核分枝杆菌对新型二芳基喹啉 ATP 合成酶抑制剂的耐药率及耐药机制。
Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8. doi: 10.1128/AAC.01611-09. Epub 2009 Dec 28.
3
Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development.迈向结核病优化治疗？临床试验和临床前开发中的药物。
Clin Chest Med. 2009 Dec;30(4):755-68, ix. doi: 10.1016/j.ccm.2009.08.011.
4
Linezolid: a review of safety and tolerability.利奈唑胺：安全性与耐受性综述
J Infect. 2009 Sep;59 Suppl 1:S59-74. doi: 10.1016/S0163-4453(09)60009-8.
5
Synthesis of novel [1,2]-diamines with antituberculosis activity.具有抗结核活性的新型[1,2]-二胺的合成
Bioorg Med Chem Lett. 2009 Sep 15;19(18):5372-5. doi: 10.1016/j.bmcl.2009.07.126. Epub 2009 Aug 6.
6
Effects of antibiotics and a proto-oncogene homolog on destruction of protein translocator SecY.抗生素和一种原癌基因同源物对蛋白质转运体SecY破坏的影响。
Science. 2009 Aug 7;325(5941):753-6. doi: 10.1126/science.1172221.
7
The use of ribosomal crystal structures in antibiotic drug design.核糖体晶体结构在抗生素药物设计中的应用。
Curr Opin Investig Drugs. 2009 Aug;10(8):750-65.
8
Role of reactive oxygen species in antibiotic action and resistance.活性氧在抗生素作用及耐药性中的作用
Curr Opin Microbiol. 2009 Oct;12(5):482-9. doi: 10.1016/j.mib.2009.06.018. Epub 2009 Jul 31.
9
The mechanism of action of PA-824: Novel insights from transcriptional profiling.PA - 824的作用机制：转录谱分析的新见解
Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.
10
Experimental models of tuberculosis: can we trust the mouse?结核病的实验模型：我们能信任小鼠模型吗？
Am J Respir Crit Care Med. 2009 Aug 1;180(3):201-2. doi: 10.1164/rccm.200905-0708ED.
Zotero 插件